II. To compare neurotoxicity in patients with advanced ovarian cancer treated with NAC followed by CRS with HIPEC versus NAC followed by CRS and postoperative IP chemotherapy III. To compare abdominal discomfort in patients with advanced ovarian cancer treated with NAC followed by CRS with HIPEC versus NAC followed by CRS and postoperative IP chemotherapy IV. To compare toxicities in patients with advanced ovarian cancer treated with NAC followed by CRS with HIPEC versus NAC followed by CRS and postoperative IP chemotherapy.